NUVA · Nuvasive Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $1.20B | $1.14B | $1.05B | $1.17B | $962.13M | - |
| Cost of Revenue | $336.51M | $322.28M | $321.63M | $312.36M | $240.10M | - |
| Gross Profit | $865.43M | $816.71M | $728.95M | $855.71M | $790.55M | $760.51M |
| R&D | $79.84M | $92.63M | $79.84M | $72.38M | $61.70M | $50.42M |
| SG&A | $634.10M | $610.09M | $547.20M | $611.18M | $575.84M | $539.91M |
| Total Operating Expenses | $777.02M | $828.74M | $690.65M | $732.66M | $736.39M | $647.16M |
| D&A | $147.03M | $149.52M | $140.94M | $135.59M | $129.76M | $121.18M |
| Operating Income | $52.32M | ($58.38M) | ($47.55M) | $80.52M | $8.72M | $74.22M |
| Interest Expense | $17.42M | $21.06M | $70.47M | $38.52M | $37.86M | $38.02M |
| Income Tax | $11.91M | $5.70M | ($10.39M) | $15.28M | ($3.76M) | ($7.04M) |
| Net Income | $40.41M | ($64.09M) | ($37.15M) | $65.23M | $12.48M | $83.01M |
| EPS - Basic | $0.78 | ($1.24) | ($0.72) | $1.26 | $0.24 | $1.63 |
| EPS - Diluted | $0.76 | ($1.24) | ($0.72) | $1.23 | $0.24 | $1.50 |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $248.66M | $246.09M | $856.87M | $213.03M | $117.84M | $72.80M |
| Accounts Receivable | $249.37M | $214.40M | $207.07M | $211.53M | $196.49M | $199.04M |
| Inventory | $338.60M | $315.85M | $300.62M | $312.42M | $273.24M | $247.25M |
| Accounts Payable | $20.32M | $16.19M | $17.39M | $11.83M | $8.80M | $4.37M |
| Current Assets | $865.21M | $802.42M | $1.56B | $764.34M | $618.21M | $558.99M |
| Total Assets | $2.22B | $2.15B | $2.69B | $1.89B | $1.71B | $1.64B |
| Current Liabilities | $716.05M | $200.89M | $836.36M | $206.92M | $179.46M | $160.67M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $915.21M | $795.21M | $918.92M | $915.21M | $834.52M | $795.31M |
| Retained Earnings | $86.11M | $45.71M | $45.32M | $82.47M | $17.24M | $4.50M |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $169.12M | $182.17M | $185.91M | $235.29M | $158.09M | $178.98M |
| Investing Cash Flow | ($155.19M) | ($136.06M) | ($281.93M) | ($134.48M) | ($304.88M) | ($174.86M) |
| Financing Cash Flow | ($8.59M) | ($653.35M) | $736.66M | ($6.64M) | $110.82M | ($87.03M) |
| CapEx | $139.23M | $111.11M | $105.73M | $122.88M | $101.92M | $110.22M |
| Free Cash Flow | $29.89M | $71.06M | $80.18M | $112.41M | $56.16M | $68.76M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 72.0% | 71.7% | 69.4% | 73.3% | 82.2% | - |
| Operating margin | 4.4% | -5.1% | -4.5% | 6.9% | 0.9% | - |
| EBITDA margin | 16.6% | 8.0% | 8.9% | 18.5% | 14.4% | - |
| Net margin | 3.4% | -5.6% | -3.5% | 5.6% | 1.3% | - |
| Free cash flow margin | 2.5% | 6.2% | 7.6% | 9.6% | 5.8% | - |
| FCF / Net income | 0.74 | -1.11 | -2.16 | 1.72 | 4.50 | 0.83 |
| R&D / Revenue | 6.6% | 8.1% | 7.6% | 6.2% | 6.4% | - |
| SG&A / Revenue | 52.8% | 53.6% | 52.1% | 52.3% | 59.8% | - |
| Effective tax rate | 22.8% | - | - | 19.0% | -43.1% | -9.3% |
| Return on assets | 1.8% | -3.0% | -1.4% | 3.5% | 0.7% | 5.1% |
| Return on equity | 4.4% | -8.1% | -4.0% | 7.1% | 1.5% | 10.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.21 | 3.99 | 1.87 | 3.69 | 3.44 | 3.48 |
| Quick ratio | 0.74 | 2.42 | 1.51 | 2.18 | 1.92 | 1.94 |
| Cash ratio | 0.35 | 1.22 | 1.02 | 1.03 | 0.66 | 0.45 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 3.0x | -2.8x | -0.7x | 2.1x | 0.2x | 2.0x |
| Equity multiplier | 2.43 | 2.71 | 2.93 | 2.06 | 2.05 | 2.06 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.54 | 0.53 | 0.39 | 0.62 | 0.56 | - |
| Inventory turnover | 0.99 | 1.02 | 1.07 | 1.00 | 0.88 | - |
| Days sales outstanding | 76d | 69d | 72d | 66d | 75d | - |
| Days inventory outstanding | 367d | 358d | 341d | 365d | 415d | - |
| Days payable outstanding | 22d | 18d | 20d | 14d | 13d | - |
| Cash conversion cycle | 421d | 408d | 393d | 417d | 477d | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 5.5% | 8.4% | -10.1% | 21.4% | - | - |
| Revenue CAGR (3y) | 1.0% | 5.8% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | 9.2% | - |
| Gross profit growth (YoY) | 6.0% | 12.0% | -14.8% | 8.2% | 4.0% | 5.3% |
| Operating income growth (YoY) | - | -22.8% | - | 823.0% | -88.2% | 14.7% |
| Net income growth (YoY) | - | -72.5% | - | 422.8% | -85.0% | 123.5% |
| EPS growth (YoY) | - | -72.2% | - | 412.5% | -84.0% | 117.4% |
| EPS CAGR (3y) | -14.8% | - | - | 21.3% | -42.5% | - |
| EPS CAGR (5y) | -12.7% | - | - | - | 7.1% | 84.6% |
| FCF growth (YoY) | -57.9% | -11.4% | -28.7% | 100.1% | -18.3% | 1.2% |
| FCF CAGR (5y) | -15.3% | 0.9% | 44.0% | 9.4% | 2.4% | -5.0% |
| Book value growth (YoY) | 15.1% | -13.5% | 0.4% | 9.7% | 4.9% | 14.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$2.28B totalProduct$1.03B · 45.4%
Spinal Hardware$856.56M · 37.6%
Surgical Support$282.43M · 12.4%
Service$104.38M · 4.6%
Geographic
$1.14B totalUS$876.61M · 77.0%
Non Us$262.37M · 23.0%
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing NUVASIVE INC against the 5 most active filers in the same SIC group.